Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation by Gasparotto, Juciano et al.
1SCIENTIFIC REpoRTs | 7: 8795  | DOI:10.1038/s41598-017-09257-3
www.nature.com/scientificreports
Targeted inhibition of RAGE in 
substantia nigra of rats blocks 
6-OHDA–induced dopaminergic 
denervation
Juciano Gasparotto  1, Camila Tiefensee Ribeiro1, Rafael Calixto Bortolin1, Nauana Somensi1, 
Thallita Kelly Rabelo1, Alice Kunzler1, Natália Cabral Souza2, Matheus Augusto de Bittencourt 
Pasquali3, José Claudio Fonseca Moreira1 & Daniel Pens Gelain1
The receptor for advanced glycation endproducts (RAGE) is a pattern-recognition receptor associated 
with inflammation in most cell types. RAGE up-regulates the expression of proinflammatory mediators 
and its own expression via activation of NF-kB. Recent works have proposed a role for RAGE in 
Parkinson’s disease (PD). In this study, we used the multimodal blocker of RAGE FPS-ZM1, which has 
become available recently, to selectively inhibit RAGE in the substantia nigra (SN) of rats intracranially 
injected with 6-hydroxydopamine (6-OHDA). FPS-ZM1 (40 μg per rat), injected concomitantly with 
6-OHDA (10 μg per rat) into the SN, inhibited the increase in RAGE, activation of ERK1/2, Src and 
nuclear translocation of NF-kB p65 subunit in the SN. RAGE inhibition blocked glial fibrillary acidic 
protein and Iba-1 upregulation as well as associated astrocyte and microglia activation. Circulating 
cytokines in serum and CSF were also decreased by FPS-ZM1 injection. The loss of tyrosine hydroxylase 
and NeuN-positive neurons was significantly inhibited by RAGE blocking. Finally, FPS-ZM1 attenuated 
locomotory and exploratory deficits induced by 6-OHDA. Our results demonstrate that RAGE is an 
essential component in the neuroinflammation and dopaminergic denervation induced by 6-OHDA in 
the SN. Selective inhibition of RAGE may offer perspectives for therapeutic approaches.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the specific loss of the 
nigrostriatal dopaminergic neurons, causing locomotor and postural deficits. Chronic neuroinflammation has 
been reported as a major contributor to PD1. The defense mechanisms in brain are able to protect against inflam-
matory processes. However, when inflammatory stressors accumulate beyond a threshold, which has not been 
defined until date, signaling pathways for neuronal death are triggered.
The amount of evidence linking RAGE to neurodegenerative diseases such as Alzheimer’s disease, PD, and 
Huntington’s disease has been increasing in the last few years2. RAGE belongs to the superfamily of immunoglob-
ulins, which are present on the surface of many types of cells such as neurons, microglia, brain endothelial cells3 
and astrocytes4. RAGE is a very promiscuous receptor binding many proteins such as S100b, HMGB1, HSP70, 
AGEs, β-amyloid and LPS among many others. New proteins with the capacity to bind RAGE are reported 
continuously.
Many animal models have been used to elucidate the mechanisms that trigger neurodegenerative diseases. We 
chose the rat model, where 6-hydroxydopamine (6-OHDA) is administrated unilaterally. This model has been 
studied extensively and the dopaminergic denervation in this rat model is similar to that in PD5, 6.
In the present work, we used a pharmacological antagonist, FPS-ZM1, for blocking RAGE in the SN to inves-
tigate potential neuroprotective effects against 6-OHDA-induced dopaminergic denervation. FPS-ZM1 is able 
to penetrate BBB and acts as a high affinity, multimodal blocker of RAGE through V domain-mediated ligand 
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binding3. FPS-ZM1 treatment has been employed to study neurotoxicity models7, 8. FPS-ZM1 was injected into 
the same site of 6-OHDA. Proinflammatory, oxidative and neurotoxic effects of 6-OHDA in serum, CSF, and 
SN were evaluated. The results demonstrate a relationship between RAGE and 6-OHDA induced dopaminergic 
denervation in the SN. FPS-ZM1 was able to protect against most of the 6-OHDA-induced effects, suggesting that 
RAGE plays a pivotal role in the propagation/amplification of inflammatory effects and dopaminergic denerva-
tion consequent from 6-OHDA injection.
Results
RAGE is increased in the SN of 6-OHDA-treated rats. The content of immunoreactive RAGE increased 
in the SN region of 6-OHDA-administered rats as shown by immunofluorescence analysis (Fig. 1a). Injection of 
RAGE blocking peptide FPS-ZM1 into the SN concomitantly with 6-OHDA inhibited the increase in RAGE 
content. Relative quantification by western blotting showed that RAGE increased by 50% in animals adminis-
tered with 6-OHDA, which was inhibited by FPS-ZM1 by 46% (Fig. 1b). RAGE content and immunolocaliza-
tion in the contralateral (not showed) SN was not affected, as expected (Fig. 1a). Interestingly, rats injected with 
FPS-ZM1 + 6-OHDA had increased RAGE localization in blood vessels as show detailed in Fig. 1a. In Control 
and FPZ-ZM1 groups, RAGE was not detected (Fig. 1a). To identify the cells in which RAGE was induced, we 
conducted co-immunostaining of RAGE with glial fibrillary acidic protein (GFAP - astrocyte marker), Iba-1 
(microglial marker), or TH (dopaminergic neuron marker). The results showed the induction of RAGE mainly in 
TH+ cells, but not in astrocytes or microglia (Fig. 2a and b). Confocal microscopy scanning of Z-axis confirmed 
the co-localization of TH and RAGE staining in the same cells (Fig. 2c), demonstrating a different pattern of 
staining from rats treated with FPS-ZM1 and 6-OHDA, in which RAGE is typically localized in endothelial cells 
and absent in TH+ neurons (Fig. 2d). Details of Z-axis scanning are shown in supplementary figure S1a and b.
NF-kB activation in SN of 6-OHDA-injected rats is mediated by RAGE. Following ligand bind-
ing, the intracellular machinery activated by RAGE induces the dissociation of p65 and p50 subunits from the 
inhibitory IkB subunit of the NF-kB complex in the cytoplasm, leading to p65 nuclear translocation. This results 
in transcriptional activation of proinflammatory genes and up-regulation of RAGE expression, as the RAGE 
gene (AGER) is also responsive to NF-κB transcriptional activity9. The immunofluorescence images of the tran-
scriptional subunit, p65 of NF-κB show the translocation of p65 from cytoplasm to nucleus in many cells in 
6-OHDA-induced group (Fig. 3a and detail in Fig. 3b). FPS-ZM1 completely blocked the 6-OHDA-induced 
translocation of p65 to nuclei. There were negligible number of p65+ nuclei in control group (2.3 ± 1.5) or ani-
mals receiving only FPS-ZM1 (3.4 ± 1.6) (Fig. 3c).
ERK1/2 and Src activation in SN of 6-OHDA-injected rats are mediated by RAGE. RAGE ligand 
binding on cell membrane results in the activation of different protein phosphorylation cascades leading to the 
activation of transcription factors such as NF-kB10. We therefore examined the phosphorylation/activation of 
MAPKs, which are regulatory signaling molecules in inflammation and cell death and might be activated upon 
RAGE ligand binding. 6-OHDA induced the phosphorylation of ERK1/2 and Src (Fig. 4a and d), and the antag-
onist FPS-ZM1 suppressed ERK1/2 and Src activation. p38 was not inhibited to a significant extent by FPS-ZM1 
and JNK phosphorylation was not significantly altered by 6-OHDA (Fig. 4b and c). These data suggest that 
ERK1/2 and Src phosphorylation in the SN of 6-OHDA-treated rats are evoked via a RAGE-dependent pathway.
RAGE inhibition in SN blocks 6-OHDA-induced neuroinflammation. We also measured 
pro-inflammatory cytokines in CSF and serum (Fig. 5a and b). TNF-α and IL-1β were increased in CSF (110% 
and 130% respectively) and serum (70% and 150% respectively) of 6-OHDA-injected rats. FPS-ZM1 blocked the 
IL-1β increase in CSF (Fig. 5a), whereas both cytokines were blocked in serum (Fig. 5b). The administration of 
6-OHDA triggers an inflammatory process that contributes to dopaminergic denervation. RAGE is a major regu-
lator of chronic inflammation in several tissues, including CNS11. In order to assess the effect of RAGE inhibition 
on the inflammation of SN in 6-OHDA-injected rats, we evaluated the effect of RAGE inhibition on glial activa-
tion by assessing GFAP and Iba-1 immunostaining (Fig. 5c) and immunoblotting (Fig. 5d and e). The increases 
in the number of GFAP+ cells and the content of GFAP were inhibited by the presence of FSP-ZM1, indicating 
that RAGE inhibition decreases 6-OHDA-induced astrocyte activation (Fig. 5c and e). Similar effect was observed 
with Iba-1, suggesting the involvement of RAGE in 6-OHDA-induced microglia activation (Fig. 5c and d).
RAGE inhibition in SN blocks 6-OHDA-induced dopaminergic denervation. Tyrosine hydroxylase 
(TH) is the rate-limiting enzyme in catecholamine synthesis and is the golden marker for dopaminergic neurons 
in the SN12. Death of dopaminergic neurons is a hallmark of PD. Therefore, we evaluated the effect of RAGE 
inhibition over dopaminergic neurons by immunostaining TH+ neurons and on other neurons by assessing 
a general neuronal marker, neuronal nuclear antigen (NeuN). The immunofluorescence analysis for neuronal 
markers revealed a significant loss of TH+ and NeuN+ cells in the SN of animals treated with 6-OHDA (Fig. 6a). 
Western blot analysis confirmed these observations (Fig. 6b and c). The RAGE inhibitor, FPS-ZM1 blocked the 
loss of TH and NeuN positive cells when administered concomitantly with 6-OHDA (Fig. 6a–c) and rescued 
the protein content. The blocking effect of RAGE inhibition in 6-OHDA-induced dopaminergic denervation is 
shown in nigrostriatal axis (Sup. Fig. S2). In addition, the TH-immunoreactivity images are shown in whole SN 
and striatum (caudate–putamen unit) (Sup. Fig. S3).
RAGE inhibition in SN rescues locomotor, rotational and exploratory deficits induced by 
6-OHDA. Dopaminergic denervation induced by 6-OHDA is characterized by locomotor and exploratory 
deficits that can be assessed in behavioral tests. General motor performance was assessed 14 days after surgery, 
using the constant (21 RPM) rotarod test. Animals injected with 6-OHDA displayed significant reduction in the 
www.nature.com/scientificreports/
3SCIENTIFIC REpoRTs | 7: 8795  | DOI:10.1038/s41598-017-09257-3
time on rotarod (60% of the control (Fig. 7a). Rats administered with both FPS-ZM1 and 6-OHDA presented an 
improved motor ability on rotarod test (10% higher than that of 6-OHDA group).
To evaluate the effectiveness and precision of the 6-OHDA injection the rotational behavior was assessed. 
The apomorphine-induced rotation is shown in Fig. 7b. The data demonstrate that 6-OHDA administration 
Figure 1. FPS-ZM1 blocked the increase in the levels of RAGE in rats administered with 6-OHDA. Rats 
were prepared for immunofluorescence and western blotting 15 days after the injection of 6-OHDA. (a) 
Representative immunofluorescence images of SN immunostained for RAGE and DAPI (n = 10 per group). The 
ipsilateral sides are shown. The microscopy images were taken with 400 μm of magnification and the squares 
represents the location of the approximation of 100 μm. (b) Representative western blots and quantification 
of RAGE (n = 6 per group). Each color in the graph represents a group and a brain location: gray - control/
ipsilateral side; blue - FPS-ZM1/ipsilateral side; red - 6-OHDA/ipsilateral side; dark red - 6-OHDA/contralateral 
side; green - FPS-ZM1 + 6-OHDA/ipsilateral side; dark green - FPS-ZM1 + 6-OHDA/contralateral side. Values 
represent mean ± SD. One-way analysis of variance and Bonferroni Multiple Comparison post-hoc test were 
applied to all data. p values are embedded in the figure.
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induced a rotational asymmetry, with rats displaying significant increase in continuous contralateral rotations 
following apomorphine injection (mean rates of 12 ± 1.5). Animals receiving FPS-ZM1 + 6-OHDA had signifi-
cantly lower rotation rates (4.6 ± 1.2) induced by apomorphine injection. Control and FPS-ZM1 groups did not 
show any significant spontaneous rotation. The lesion severity of 6-OHDA model was established according to 
apomorphine-induced rotation13. The present model is characterized as severe, since rats exhibited more than 
3 contralateral turns/minute. This magnitude of impairment is expected to display > 85% TH+ cell loss in SN 
and > 45% TH+ cell loss in VTA13.
We also evaluated the exploratory activity. Animals administered with FPS-ZM1 + 6-OHDA presented a 
higher exploratory activity in an open field test of rearing events, compared to animals receiving only 6-OHDA 
(Fig. 7c). Notably, 6-OHDA reduced the number of rearing episodes (50% of control), whereas rats exposed to 
FPS-ZM1 + 6-OHDA displayed a higher number of rearing episodes compared to the control group (Fig. 7c).
Discussion
Although 6-OHDA-induced dopaminergic denervation has been a useful model largely utilized for under-
standing motor and biochemical dysfunctions associated to PD, it is not clear, whether dopaminergic cell death 
induced by this toxin shares common molecular mechanisms to those observed in patients. In this context, it 
must be considered that the 6-OHDA model does not replicate several pathological characteristics of PD, which 
poses limitations in relation to the interpretations of molecular mechanisms underlying the progression of dopa-
minergic cell death when using this model. For instance, animal models of 6-OHDA injection do not display 
Lewy bodies in the brain, a histopathological hallmark of PD14, 15. Besides, the dopaminergic denervation is local-
ized and rapidly induced if compared to PD. In this disease, a progressive neuronal death evolves in the course of 
years and its consequence is not restricted to dopaminergic denervation, although this is the main cause of the 
characteristic motor symptoms14. Nonetheless, animal models of PD present different limitations regarding the 
multiple dysfunctions of the disease, and the 6-OHDA animal model is still considered a valid model to investi-
gate behavioral and cellular features of PD14. Here, we performed a localized inhibition of RAGE with FPS-ZM1 
(RAGE antagonist) to understand the involvement of RAGE in dopaminergic denervation and to test a potential 
strategy to prevent and neuronal death. RAGE interacts with a variety of ligands4 that may lead to inflammatory 
response causing brain injury and cell death16. To investigate the role of RAGE in SN, we administered 6-OHDA 
to induce neuronal death and co-administered FPS-ZM1 to inhibit the action of RAGE.
RAGE is a receptor with bad reputation2, fittingly so. RAGE is implicated in numerous neurodegenerative 
disorders such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease2. Although there is ample evi-
dence demonstrating the involvement of RAGE in neurodegenerative diseases17, the mechanism by which RAGE 
Figure 2. RAGE preferentially binds to dopaminergic neurons. Rats were prepared for immunofluorescence 15 
days after 6-OHDA administration. The sections were co-immunostained for markers specific to different cell 
types and RAGE to evaluate the morphology and co-localization. (a) GFAP + RAGE, (b) IBA-1+ RAGE. The 
microscopy images were taken with 50 μm of magnification. (c) Confocal representative immunofluorescence 
images of SN co-immunostained for TH, RAGE and DAPI to ipsilateral 6-OHDA-induced and (d) ipsilateral 
FPS-ZM1 + 6-OHDA. The confocal microscopy images were taken with 100 μm of magnification and the z-axis 
layers are detailed in Sup. Fig. S1a and b. Representative immunofluorescence images of SN co-immunostained 
for different cell types (n = 10 per group): Only ipsilateral sides are showed.
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causes neuronal death remains unclear. Our results have demonstrated that 6-OHDA increased the number of 
RAGE-positive cells specifically in SN (Fig. 1a). Immunofluorescence visualization of a larger area in SN gives a 
general picture of the capacity of RAGE antibody to bind to various cell types. However, when we approximate the 
image magnification (Fig. 2c) it is possible to observe an accentuated presence of RAGE in dopaminergic neurons 
compared to that in astrocytes (Fig. 2a) and microglia (Fig. 2b).
Astrocytes are stellate-like cells and represent the most abundant cell type in most parts of the brain. The 
morphological changes induced in astrocytes by 6-OHDA (Sup. Fig. S1c) may result from changes of cytoskel-
etal proteins in microfilaments, intermediate filaments, and/or microtubules18. Microglia are highly dynamic 
cells, presenting a functional phenotype. Under both physiological and pathological conditions, they scan their 
environment and regulate tissue homeostasis19. In response to 6-OHDA lesion, microglia displayed a morphol-
ogy associated to an activated phenotype (Sup. Fig. S1d) Furthermore, 6-OHDA reduced the number of TH+ 
neurons and induced characteristic morphological changes in surviving cells. The remaining TH+ cells showed 
a spherical format in comparison to the normal spindle forms presenting a well-designed axodendritic network 
(Sup. Fig. S1e and f). The neuroplasticity induced by 6-OHDA or derived toxins is unclear, however altered cell 
morphology may be an informative tool in documenting the changes caused by the neurotoxic insults to neuronal 
and nucleolar volume20.
NF-κB is a critical factor transducing a variety of inflammatory and pro- or anti-apoptotic signals in the cell, 
depending on the stimulus21. There was a massive presence of NF-κB-p65 in the nuclei of the SN cells of rats 
receiving 6-OHDA, indicating a transcriptional effect (Fig. 3b). NF-κB translocation also promotes the expres-
sion of proinflammatory cytokines11. The gene encoding RAGE contains functional binding elements for NF-κB. 
RAGE can also upregulate itself, perpetuating the neuroinflammation21, 22. FPS-ZM1 significantly suppresses 
the ERK1/2 phosphorylation and NF-κB translocation to the nuclei of the cells in the SN of rats injected with 
6-OHDA (Fig. 3a–c). This strongly suggests that inhibiting RAGE activation blocked the signaling cascade and 
consequently blocked the inflammation and damage caused by 6-OHDA.
RAGE activation triggers MAPK-controlled phosphorylation cascades. Our results show that 6-OHDA sig-
nificantly increased ERK1/2 and Src activation (Fig. 4a and d). ERK 1/2 is the main component of the MAPK 
pathway and when enhanced by prior Src phosphorylation, it plays a key role in RAGE signal, which may result 
in the upregulation of NF-κB23. In addition RAGE directly binds to ERK by a D-like domain, this interaction does 
Figure 3. FPS-ZM1 blocked the 6-OHDA-induced nuclear translocation of NF-κB-p65. Rats were prepared for 
immunofluorescence 15 days after 6-OHDA administration. (a) Representative co-immunofluorescence images 
of SN immunostained for NF-κB-p65, RAGE and DAPI (n = 10 per group). The ipsilateral sides are showed. The 
microscopy images were taken with 50 μm of magnification. (b) Cell details. (c) p65+ nucleus quantification/
picture with 50 μm magnification area. Values represent mean ± SD from 6 rats per group. One-way analysis of 
variance and Bonferroni Multiple Comparison post-hoc test were applied to all data. p values are embedded in 
the figure.
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not occur with others MAPKs as for p38 and JNK23. RAGE seems to have an important effect in this pathway, 
whereas FPS-ZM1 blocked the 6-OHDA-induced signaling otherwise activated by RAGE.
We observed an increase in TNF-α and IL-1β in 6-OHDA-induced rats, as demonstrated by the ELISA meas-
urements in CSF and serum (Fig. 5a and b). The increases in these cytokines originate from many cells stimulated 
by 6-OHDA, mainly astrocytes and microglia, which overproduce and release TNF-α and IL-1β into CSF and 
serum. 6-OHDA generates a strong pro-inflammatory response and inflammatory condition in distinct cell types. 
Inhibiting RAGE with FPS-ZM1 blocked the release of cytokines (TNF-α in CSF was the exception) and the 
activation of astrocytes and microglia in SN (Fig. 5c–e). Taking these results together, RAGE seems to be a crucial 
factor that mediates the 6-OHDA-induced inflammatory process and contributes to neuronal degeneration.
Research with animal models and clinical studies suggested that RAGE4, protein S100B24 and HMGB125 are 
potential contributors to the development of PD. These data are in accordance with our results and support our 
research focus to block RAGE, since inflammatory signaling and neuronal damage seem to occur through this 
receptor.
6-OHDA administration, as expected, reduced the number of TH and NeuN positive neurons (Fig. 6a–c). 
FPS-ZM1 protected against 6-OHDA-induced effects. These results provide strong evidence for the hypoth-
esis that RAGE inhibition blocks all signaling cascades involved in neuroinflammation and dopaminergic 
denervation. The neuronal death in SN manifested in locomotor deficit was confirmed by rotarod test and 
apomorphine-induced rotations (Fig. 7a and b). In addition, the animals displayed depression-like behavior and 
decrease in exploratory interest (Fig. 7c) that is correlated with DA impairments26. FPS-ZM1 also protects against 
6-OHDA-induced behavioral changes. There was an increase in exploratory interest, probably because there was 
an increase in the expression of neurotransmitters. The behavioral impairments along with reduced number of 
neurons in the SN provide concrete evidence for the progressive death of DA neurons. FPS-ZM1 protects against 
this effect of 6-OHDA.
Figure 4. FPS-ZM1 inhibited 6-OHDA-induced MAPK-ERK 1/2 and Src phosphorylation. Tissue samples 
were prepared for western blotting assay 15 days after 6-OHDA-injection. (a) p-ERK 1/2. (b) p-p38. (c) p-JNK. 
(d) p-Src. The representative western blots of phosphorylated protein and total protein are shown below the 
graphs. Values represent mean ± SD from 6 rats per group. One-way analysis of variance and Bonferroni 
Multiple Comparison post-hoc test were applied to all data. p values are embedded in the figure.
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Conclusion
The multimodal blocker of RAGE, FPS-ZM1, shows a neuroprotective activity in the rat model of 
6-OHDA-induced PD. FPS-ZM1 injected in the SN blocked dopaminergic denervation, neuroinflammation, 
and locomotor/exploratory deficits induced by 6-OHDA. The probable chain of events triggered by 6-OHDA 
in the SN of rats, according to our results, includes RAGE activation and upregulation, followed by activation 
of downstream signaling that involves ERK1/2 and Src, leading to p65 nuclear translocation and consequent 
pro-inflammatory response. This latter effect results in activation of astrocytes and microglia and increased 
Figure 5. FPS-ZM1 protected rats from 6-OHDA-induced neuronal inflammation. CSF and serum were 
analyzed by ELISA assay 15 days after 6-OHDA administration. (a) Cerebrospinal fluid was analyzed for 
TNF-α and IL-1β. TNF-α and IL-1β levels are expressed in pg/mL. (b) Serum samples were analyzed for 
TNF-α and IL-1β. (c) Representative immunofluorescence images of SN co-immunostained for IBA-1, GFAP 
and DAPI (n = 10 per group). The ipsilateral sides are shown. The microscopy images were taken with 400 
μm of magnification and the squares represents the location of the approximation of 100 μm. Representative 
western blots and quantification of (d) IBA-1 (n = 6 per group) and (e) GFAP (n = 6 per group). Each color in 
the graph represents a group and a brain location: gray - control/ipsilateral side; blue - FPS-ZM1/ipsilateral 
side; red - 6-OHDA/ipsilateral side; dark red - 6-OHDA/green - FPS-ZM1 + 6-OHDA/ipsilateral side; dark 
green - FPS-ZM1 + 6-OHDA/contralateral side. Values represent mean ± SD. One-way analysis of variance and 
Bonferroni Multiple Comparison post-hoc test were applied to all data. p values are embedded in the figure.
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Figure 6. FPS-ZM1 inhibited 6-OHDA-induced neuronal death. Tissues were prepared for 
immunofluorescence and western blotting 15 days after 6-OHDA administration. (a) Representative 
immunofluorescence images of SN immunostained for TH, NeuN, and DAPI (n = 10 per group). The ipsilateral 
sides are shown. The microscopy images were taken with 400 μm of magnification and the squares represents 
the approximation to 100 μm. (b) Representative western blots and quantification of NeuN (n = 6 per group) 
and c) TH (n = 6 per group). Each color in the graph represents a group and a brain location: gray - control/
ipsilateral side; blue - FPS-ZM1/ipsilateral side; red - 6-OHDA/ipsilateral side; dark red - 6-OHDA/contralateral 
side; green - FPS-ZM1 + 6-OHDA/ipsilateral side; dark green - FPS-ZM1 + 6-OHDA/contralateral side. Values 
represent mean ± SD. One-way analysis of variance and Bonferroni Multiple Comparison post-hoc test were 
applied to all data. p values are embedded in the figure.
Figure 7. FPS-ZM1 protects rats from 6-OHDA-induced motor deficits. Locomotor abilities of rats injected 
with 6-OHDA were examined 14 days after the injection. (a) Rotarod test – total time on the rod limited to 
4 min. (b) Rotational activity after apomorphine challenging. (c) Open field rearing test - duration limited 
to 5 min. Values represent mean ± SD from ten rats per group. One-way analysis of variance and Bonferroni 
Multiple Comparison post-hoc test were applied to all data. p values are embedded in the figure. n = 12 per 
group was used for rotarod and rearing test, n = 10 per group was used to measure the rotational activity.
www.nature.com/scientificreports/
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circulating cytokines in CSF and serum. This, in turn, contributes to cell death and consequent loss of dopamin-
ergic neurons (neurodegeneration), which is reflected in the deficits in locomotory and exploratory behavior. 
FPS-ZM1 was effective in blocking the dopaminergic denervation induced by 6-OHDA. However, it did not 
bring back the rotarod performance to control levels, indicating that molecular pathways other than RAGE also 
contribute to locomotor deficits caused by 6-OHDA, which is expected. Co-localization immunofluorescence 
results indicate that neurons are the main cells expressing RAGE in the SN of 6-OHDA-injected rats. Despite the 
limitations of this model, the present results indicate that the potential application of RAGE pharmacological 
inhibition in PD and the understanding of the role of this receptor in the pathophysiology of this disease must be 
investigated in more details.
Methods
Chemicals. Electrophoresis and immunoblotting apparatus were from Bio-Rad (Hercules, USA) and GE 
Healthcare Brazilian Headquarter (Sao Paulo, Brazil), respectively. The antibody information is listed in the 
descriptions of each technique. All other reagents used in this study were of analytical or HPLC grade.
Ethics Statement. Our research protocol was approved under project number 27683 by the Ethical 
Committee for Animal Experimentation of the Universidade Federal do Rio Grande do Sul-Brazil 
(CEUA-UFRGS). All experimental procedures were performed in accordance with the guidelines of the National 
Institutes of Health27 and the Brazilian Society for Neuroscience and Behavior recommendations for animal care. 
All efforts were made to minimize animal suffering.
Animals. Male Wistar rats (60 days old) bred in our facilities were maintained at constant temperature of 
21 ± 1 °C and 12-hour light–dark cycle. They were caged in groups of four animals with free access (ad libitum) 
to water and standard commercial food (Chow Nuvilab CR-1 type; PR, Brazil). The rats were anesthetized with a 
single dose of ketamine (100 mg/kg; i.p.) and xilazine (10 mg/kg; i.p.) for all surgical procedures.
FPS-ZM1 and 6-hydroxydopamine (6-OHDA) preparation. FPS-ZM1 (C20H22ClNO) is a non-toxic, 
tertiary amide compound that acts as a high affinity multimodal blocker of RAGE V domain-mediated ligand 
binding (Ki = 25, 148, & 230 nM)3. It was dissolved in a small amount of dimethylsulfoxide (DMSO) and then 
diluted with saline to 10 μg/μL stock solution. The final DMSO concentration was 0.02%. FPS-ZM1 was pur-
chased from Merck Millipore (MA, USA). Each rat received injection with 40 μg of FPS-ZM1 into the SN. 
6-OHDA is a neurotoxic synthetic organic compound that destroys catecholaminergic terminals. It was prepared 
as a 5 μg/μL solution in 0.02% ascorbic acid dissolved in sterile saline, protected from heat and light. 6-OHDA was 
purchased from Sigma-Aldrich® (MO, USA). Each rat was administered with 10 μg28 of 6-OHDA.
Experimental design. The rats were randomly divided into four groups:
Group 1: control group received intranigral injection of saline solution.
Group 2: received FPS-ZM1 (intranigral injection).
Group 3: received 6-OHDA (intranigral injection).
Group 4: received FPS-ZM1 + 6-OHDA (intranigral injection).
Fourteen days after the induction of the SN lesion (see below), behavior tests were performed. On the 15th 
day, all the animals were anaesthetized and CSF was sampled. Six animals from each group were decapitated and 
serum was collected, followed by dissection of the SN for analysis. Ten animals in each group were intracardially 
perfused for immunoflorescence assessment.
Surgical Procedure. Anesthetized rats were immobilized by securing via ear and nose bars on a stereotaxic 
apparatus (Insight-EFF 338, SP, BRA). Fur was shaved with a pet clipper (SKU #: 09160-210 – Wahl; IL, USA) 
and 10% povidone-iodine solution was applied to sterilize the incision site. The skulls were trepanned with a 
dental drill (3 mm) at the appropriate location. A single dose (2 μL) of 6-OHDA28 or FPS-ZM13 or saline was 
injected into the left SN at the following stereotaxic coordinates: antero-posterior (AP): −5.0 mm from bregma; 
medio-lateral (ML): ± 2.1 mm from the midline; dorso-ventral (DV): −8.0 mm from skull, according to the Rat 
Brain Atlas in Stereotaxic Coordinates Paxinos29, using a 10-μl Hamilton® syringe 701SN, needle size 23s ga 
(Sigma-Aldrich®; MO, USA). Syringes were lowered into the brain at a rate of 2 mm/min. The chemicals were 
injected at a rate of 0.5 μL/min and the syringe was left in place for 2 min after injection, before drawing back 
at a rate of 2 mm/min. The incision was thoroughly cleaned with povidone-Iodine solution and closed using 
three sutures. Lactated Ringer’s solution (1 mL) was injected subcutaneously to replenish electrolytes. Nebacetin 
(Medley; RS, BRA) was applied topically to the incision to prevent infections. The animals were removed from 
stereotaxic frame and placed in a controlled temperature recovery cage (37 °C) until they regained consciousness. 
The animals were returned to the housing facility 2 h after the surgery.
Immunofluorescence microscopy. Fifteen days after the surgery, rats were perfused via the vascular sys-
tem with descending aorta clamped. Sterile saline was administered for 10 min followed by perfusion with 4% 
paraformaldehyde (PFA) solution in PBS, pH 7.4, for 10 more minutes. The brains were then carefully recovered 
and maintained in 4% PFA for 24 h at 4 °C. The brains were then transferred into 15% sucrose solution for 24 h 
at 4 °C followed by immersion in 30% sucrose for additional 24 h at 4 °C. Brains were lightly dried and frozen 
at −20 °C. After 24 h, the SN region was sectioned in to slices of 15 μm thickness on the coronal plane using 
a cryostat at −20 °C (Jung Histoslide 2000R; Leica; Heidelberg, Germany). A total of 20–30 slices per rat con-
taining SN were collected in PBS containing 0.1% triton ×100. The free-floating sections were incubated in 5% 
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albumin for 2 h to block nonspecific binding. The sections were then incubated with antibodies for 48 h at 4 °C. 
The details of the antibody source and dilutions are as follows. Anti-GFAP (1:500- G6171) and DAPI for nucleic 
acid staining (1:500; D9542) were from Sigma-Aldrich® (MO, USA). Anti-IBA-1 (1:500; 019-19741) was from 
Wako Chemicals USA, Inc. (VA, USA). Anti-RAGE (1:200; PA1-84173) was from Thermo Fisher Scientific (MA, 
USA). Anti-NeuN (1:500; MAB377) was from Merck Millipore (MA, USA). Anti-NF-κB -p65 (1:200; 6956) and 
Anti-TH (1:200; 2792 S) were from Cell Signaling Technology® (MA, USA). Antibodies were diluted in PBS 
containing 2% bovine serum albumin. Primary antibodies were excluded from the incubation of negative con-
trols. After washing four times with 0.1% PBS, tissue sections were incubated with secondary antibodies, which 
included anti-rabbit Alexa 488 or 555; anti-mouse Alexa 488 or 555 and Alexa anti-goat 555 from Cell Signaling 
Technology® (MA, USA), all of them diluted 1:500 in PBS containing 2% BSA. After incubation in second-
ary antibodies for 1 h at room temperature (21 ± 3 °C), the sections were washed several times in 0.1% PBS, 
transferred to gelatinized slides, mounted with FluorSave™ (345789- Merck Millipore; MA, USA) and covered 
with coverslips. The images were acquired using a Microscopy EVOS® FL Auto Imaging System (AMAFD1000 
- Thermo Fisher Scientific; MA, USA). The Z-axis images were collected using a Laser-scanning confocal micros-
copy (Olympus FV 1000, Tokyo, Japan).
Enzyme-linked immunosorbent assay (ELISA) determination of cytokines. TNF-α (RAB0479-
1KT) and IL-1β (RAB0272-1KT) were quantified with commercial kits from Sigma-Aldrich® (MO, USA). The 
CSF from cisterna magna and blood serum samples were incubated in ELISA plates and processed further 
according to the manufacturer’s protocol.
Western blotting. For immunoblotting experiments, tissues were prepared using a radioimmunoprecip-
itation assay buffer protocol30. Total proteins (30 μg/well) were fractionated by SDS-PAGE and electroblotted 
onto nitrocellulose membranes with Trans-Blot Semi-Dry Electrophoretic Transfer Cell (Bio-Rad; CA, USA). 
Protein loading and electroblotting efficiency were verified through Ponceau S staining. After washing with TTBS 
(100 mM Tris – HCl, pH 7.5, containing 0.9% NaCl, and 0.1% Tween-20), the membranes were incubated with 
primary antibodies (1:500 dilutions) for 20 min at room temperature in SNAP i.d. 2.0 Protein Detection System 
(Merck Millipore; MA, USA). The membranes were washed again with TTBS. Polyclonal and monoclonal anti-
bodies used were from Cell Signaling Technology® (MA, USA) and included the following: anti-p-ERK-44/42 
(Thr202/Tyr204) (9101), anti-ERK-44/42 (9102), anti-p-Src (Tyr416) (2101), anti-Src (2108), p-p38 (4511), 
anti-p38 (8690), anti-p-SAPK/JNK (Thr183/Tyr185) (9255), and anti-SAPK/JNK (9252). The blots were incu-
bated with anti-rabbit, goat or mouse peroxidase-linked secondary antibody for an additional 20 min in SNAP 
(1:5000 dilution) and washed again. The immunoreactivity was detected by enhanced chemiluminescence using 
Supersignal West Pico Chemiluminescent kit from Thermo Fisher Scientific (MA, USA). The chemiluminescence 
was captured with an ImageQuant LAS 4000 (GE Healthcare; SP, Brazil). Densitometric analysis of the images 
were performed using ImageJ software (ImageJ v1.49, National Institute of Health, USA). Blots were developed to 
be linear in the range used for densitometry. All results were expressed as relative ratio to β-actin (A1978) from 
Sigma-Aldrich® (MO, USA) or total protein content.
Behavioral tests (locomotor, rotational and exploratory activities). The motor system was eval-
uated using the rotarod test. The protocol was performed at a constant speed of 21 rpm. The cut-off time was 
240 s31. The animals were acclimated to the apparatus with three prior training sessions at one-hour intervals. 
The duration on rotarod during experimental sessions was measured. The mean of 3 attempts were used for the 
statistical analyses.
Apomorphine-induced rotation test was performed to study the hypersensitivity of the lesioned SN. 
Apomorphine 0.1 mg/kg (dissolved in a 0.2 mg/mL ascorbic acid in 0.9% saline solution) was subcutaneously 
injected and tested over a 40 min session. Animals were allowed to habituate for 5 min after injection before the 
recording of rotations began in cylinder rotameter (400 mm diameter). Full body ipsilateral and contralateral side 
rotations were counted by an observer who was blind to the animal pretreatments. The data were expressed as 
the net (contralateral - ipsilateral turns) average rotations per min (RPM)32. Apomorphine was purchased from 
Sigma-Aldrich®; MO, USA.
The other parameter evaluated was the number of rearing events. In an open field test, the rearing episodes 
were scored when the animal displayed a vertical exploratory activity33.
Protein assay. Total protein was quantified by Bradford assay and used to normalize all data34.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 7 (GraphPad Software 
Inc., CA, USA). Data were evaluated by one-way ANOVA followed by Bonferroni multiple comparison post-hoc 
test. The results are expressed as mean ± SD. Differences were considered significant when p < 0.05.
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